Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 6/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2193737 | 0.84 | HCAR1 (0.65) | HCAR1GAAJAK1ALDH1A1HPGD | |
| SCHEMBL2195952 | 0.83 | HCAR1 (0.47) | HCAR1HSD17B10GAAJAK1HDAC1 | |
| SCHEMBL2195250 | 0.83 | HCAR1 (0.47) | HCAR1HSD17B10GAAJAK1HDAC1 | |
| SCHEMBL2193662 | 0.82 | HCAR1 (0.48) | HCAR1HSD17B10GAAJAK1HDAC1 | |
| SCHEMBL2195177 | 0.82 | HCAR1 (0.48) | HCAR1HSD17B10GAAJAK1HDAC1 | |
| SCHEMBL2195668 | 0.82 | HCAR1 (0.48) | HCAR1HSD17B10GAAJAK1HDAC1 | |
| SCHEMBL2195406 | 0.75 | HCAR1 (0.51) | HCAR1HSD17B10GAAJAK1 | |
| SCHEMBL2193525 | 0.74 | HCAR1 (0.50) | HCAR1HSD17B10GAAHDAC1NPC1 | |
| SCHEMBL2192372 | 0.74 | HCAR1 (0.50) | HCAR1JAK1 | |
| SCHEMBL3647369 | 0.73 | JAK1 (0.39) | JAK1USP2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507473-B2 | 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20110172209-A1 | 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172209-A1 | 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS | GPR84, GPR119, GPR65 | HCAR1 28/4885HSD17B10 1203/4885GAA 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.